Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 2,000
Single User License Price INR 135
Corporate User License Price USD 6,000
Corporate User License Price INR 405
Site License Price USD 4,000
Site License Price INR 270
Request a Quote

Report Title

Myelodysplastic Syndrome - Pipeline Review, H1 2018

Quote Request for License Type
License Type Price  
Single User License USD 2,000
Site License USD 4,000
Enterprise Wide License USD 6,000
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Myelodysplastic Syndrome - Pipeline Review, H1 2018


Quote Request for License Type
License Type Price  
Single User License USD 2,000
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Myelodysplastic Syndrome - Pipeline Review, H1 2018

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Myelodysplastic Syndrome - Pipeline Review, H1 2018



Executive Summary

Myelodysplastic Syndrome - Pipeline Review, H1 2018

 

Summary

 

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Myelodysplastic Syndrome - Pipeline Review, H1 2018, provides an overview of the Myelodysplastic Syndrome (Oncology) pipeline landscape.

 

Myelodysplastic syndrome (MDS) is a condition that affects the bone marrow and the blood cells it produces. Myelodysplastic syndromes rarely cause signs or symptoms in the early stages of the disease. Symptoms include fatigue, shortness of breath, unusual paleness (pallor) due to anemia, easy or unusual bruising or bleeding and frequent infections.

 

Report Highlights

 

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Myelodysplastic Syndrome - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Myelodysplastic Syndrome (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

 

The Myelodysplastic Syndrome (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Myelodysplastic Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 13, 69, 51, 3, 19 and 9 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical, Discovery and Unknown stages comprises 8, 9, 3, 2 and 2 molecules, respectively.

 

Myelodysplastic Syndrome (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

 

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

 

Scope

 

- The pipeline guide provides a snapshot of the global therapeutic landscape of Myelodysplastic Syndrome (Oncology).

- The pipeline guide reviews pipeline therapeutics for Myelodysplastic Syndrome (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Myelodysplastic Syndrome (Oncology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Myelodysplastic Syndrome (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Myelodysplastic Syndrome (Oncology)

 

Reasons to buy

 

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Myelodysplastic Syndrome (Oncology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Myelodysplastic Syndrome (Oncology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents 2

Introduction 8

Myelodysplastic Syndrome - Overview 9

Myelodysplastic Syndrome - Therapeutics Development 10

Myelodysplastic Syndrome - Therapeutics Assessment 32

Myelodysplastic Syndrome - Companies Involved in Therapeutics Development 50

Myelodysplastic Syndrome - Drug Profiles 97

Myelodysplastic Syndrome - Dormant Projects 967

Myelodysplastic Syndrome - Discontinued Products 973

Myelodysplastic Syndrome - Product Development Milestones 975

Appendix 986

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Number of Products under Development for Myelodysplastic Syndrome, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1 2018

List of Tables

Number of Products under Development for Myelodysplastic Syndrome, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Myelodysplastic Syndrome - Pipeline by 4SC AG, H1 2018

Myelodysplastic Syndrome - Pipeline by AbbVie Inc, H1 2018

Myelodysplastic Syndrome - Pipeline by Acceleron Pharma Inc, H1 2018

Myelodysplastic Syndrome - Pipeline by Actinium Pharmaceuticals Inc, H1 2018

Myelodysplastic Syndrome - Pipeline by Aeglea BioTherapeutics Inc, H1 2018

Myelodysplastic Syndrome - Pipeline by Agios Pharmaceuticals Inc, H1 2018

Myelodysplastic Syndrome - Pipeline by Aileron Therapeutics Inc, H1 2018

Myelodysplastic Syndrome - Pipeline by AIMM Therapeutics BV, H1 2018

Myelodysplastic Syndrome - Pipeline by Altor BioScience Corp, H1 2018

Myelodysplastic Syndrome - Pipeline by Amgen Inc, H1 2018

Myelodysplastic Syndrome - Pipeline by Angiocrine Bioscience Inc, H1 2018

Myelodysplastic Syndrome - Pipeline by Apogenix AG, H1 2018

Myelodysplastic Syndrome - Pipeline by Aprea AB, H1 2018

Myelodysplastic Syndrome - Pipeline by Aptevo Therapeutics Inc, H1 2018

Myelodysplastic Syndrome - Pipeline by arGEN-X BV, H1 2018

Myelodysplastic Syndrome - Pipeline by Array BioPharma Inc, H1 2018

Myelodysplastic Syndrome - Pipeline by Astex Pharmaceuticals Inc, H1 2018

Myelodysplastic Syndrome - Pipeline by AstraZeneca Plc, H1 2018

Myelodysplastic Syndrome - Pipeline by Atara Biotherapeutics Inc, H1 2018

Myelodysplastic Syndrome - Pipeline by Bayer AG, H1 2018

Myelodysplastic Syndrome - Pipeline by Bellicum Pharmaceuticals Inc, H1 2018

Myelodysplastic Syndrome - Pipeline by BerGenBio ASA, H1 2018

Myelodysplastic Syndrome - Pipeline by Bio-Path Holdings Inc, H1 2018

Myelodysplastic Syndrome - Pipeline by BioLineRx Ltd, H1 2018

Myelodysplastic Syndrome - Pipeline by Boehringer Ingelheim GmbH, H1 2018

Myelodysplastic Syndrome - Pipeline by Boston Biomedical Inc, H1 2018

Myelodysplastic Syndrome - Pipeline by Bristol-Myers Squibb Co, H1 2018

Myelodysplastic Syndrome - Pipeline by Calithera Biosciences Inc, H1 2018

Myelodysplastic Syndrome - Pipeline by Cantex Pharmaceuticals Inc, H1 2018

Myelodysplastic Syndrome - Pipeline by Celgene Corp, H1 2018

Myelodysplastic Syndrome - Pipeline by Cell Medica Ltd, H1 2018

Myelodysplastic Syndrome - Pipeline by Cellectis SA, H1 2018

Myelodysplastic Syndrome - Pipeline by Cellerant Therapeutics Inc, H1 2018

Myelodysplastic Syndrome - Pipeline by Celyad SA, H1 2018

Myelodysplastic Syndrome - Pipeline by CrystalGenomics Inc, H1 2018

Myelodysplastic Syndrome - Pipeline by CTI BioPharma Corp, H1 2018

Myelodysplastic Syndrome - Pipeline by Cyclacel Pharmaceuticals Inc, H1 2018

Myelodysplastic Syndrome - Pipeline by Daiichi Sankyo Co Ltd, H1 2018

Myelodysplastic Syndrome - Pipeline by Deciphera Pharmaceuticals LLC, H1 2018

Myelodysplastic Syndrome - Pipeline by Eisai Co Ltd, H1 2018

Myelodysplastic Syndrome - Pipeline by Eli Lilly and Co, H1 2018

Myelodysplastic Syndrome - Pipeline by F. Hoffmann-La Roche Ltd, H1 2018

Myelodysplastic Syndrome - Pipeline by Fate Therapeutics Inc, H1 2018

Myelodysplastic Syndrome - Pipeline by Forma Therapeutics Inc, H1 2018

Myelodysplastic Syndrome - Pipeline by Formation Biologics Inc, H1 2018

Myelodysplastic Syndrome - Pipeline by Fortress Biotech Inc, H1 2018

Myelodysplastic Syndrome - Pipeline by Forty Seven Inc, H1 2018

Myelodysplastic Syndrome - Pipeline by Fujifilm Holdings Corporation, H1 2018

Myelodysplastic Syndrome - Pipeline by Gadeta BV, H1 2018

Myelodysplastic Syndrome - Pipeline by Gamida Cell Ltd, H1 2018

Myelodysplastic Syndrome - Pipeline by GlaxoSmithKline Plc, H1 2018

Myelodysplastic Syndrome - Pipeline by H3 Biomedicine Inc, H1 2018

Myelodysplastic Syndrome - Pipeline by Humanigen Inc, H1 2018

Myelodysplastic Syndrome - Pipeline by IGF Oncology LLC, H1 2018

Myelodysplastic Syndrome - Pipeline by Imago BioSciences Inc, H1 2018

Myelodysplastic Syndrome - Pipeline by Immune System Key Ltd, H1 2018

Myelodysplastic Syndrome - Pipeline by Incyte Corp, H1 2018

Myelodysplastic Syndrome - Pipeline by Io Therapeutics Inc, H1 2018

Myelodysplastic Syndrome - Pipeline by Jazz Pharmaceuticals Plc, H1 2018

Myelodysplastic Syndrome - Pipeline by Johnson & Johnson, H1 2018

Myelodysplastic Syndrome - Pipeline by JW Pharmaceutical Corp, H1 2018

Myelodysplastic Syndrome - Pipeline by Kainos Medicine Inc, H1 2018

Myelodysplastic Syndrome - Pipeline by Karyopharm Therapeutics Inc, H1 2018

Myelodysplastic Syndrome - Pipeline by Kiadis Pharma NV, H1 2018

Myelodysplastic Syndrome - Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2018

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

4SC AG

AbbVie Inc

Acceleron Pharma Inc

Actinium Pharmaceuticals Inc

Aeglea BioTherapeutics Inc

Agios Pharmaceuticals Inc

Aileron Therapeutics Inc

AIMM Therapeutics BV

Altor BioScience Corp

Amgen Inc

Angiocrine Bioscience Inc

Apogenix AG

Aprea AB

Aptevo Therapeutics Inc

arGEN-X BV

Array BioPharma Inc

Astex Pharmaceuticals Inc

AstraZeneca Plc

Atara Biotherapeutics Inc

Bayer AG

Bellicum Pharmaceuticals Inc

BerGenBio ASA

Bio-Path Holdings Inc

BioLineRx Ltd

Boehringer Ingelheim GmbH

Boston Biomedical Inc

Bristol-Myers Squibb Co

Calithera Biosciences Inc

Cantex Pharmaceuticals Inc

Celgene Corp

Cell Medica Ltd

Cellectis SA

Cellerant Therapeutics Inc

Celyad SA

CrystalGenomics Inc

CTI BioPharma Corp

Cyclacel Pharmaceuticals Inc

Daiichi Sankyo Co Ltd

Deciphera Pharmaceuticals LLC

Eisai Co Ltd

Eli Lilly and Co

F. Hoffmann-La Roche Ltd

Fate Therapeutics Inc

Forma Therapeutics Inc

Formation Biologics Inc

Fortress Biotech Inc

Forty Seven Inc

Fujifilm Holdings Corporation

Gadeta BV

Gamida Cell Ltd

GlaxoSmithKline Plc

H3 Biomedicine Inc

Humanigen Inc

IGF Oncology LLC

Imago BioSciences Inc

Immune System Key Ltd

Incyte Corp

Io Therapeutics Inc

Jazz Pharmaceuticals Plc

Johnson & Johnson

JW Pharmaceutical Corp

Kainos Medicine Inc

Karyopharm Therapeutics Inc

Kiadis Pharma NV

Kyowa Hakko Kirin Co Ltd

La Jolla Pharmaceutical Company

Les Laboratoires Servier SAS

Lixte Biotechnology Holdings Inc

MacroGenics Inc

Madrigal Pharmaceuticals Inc.

Mateon Therapeutics Inc

MediGene AG

MedImmune LLC

Medivir AB

MEI Pharma Inc

Merck & Co Inc

Merus NV

Millennium Pharmaceuticals Inc

NantKwest Inc

Nippon Shinyaku Co Ltd

Nohla Therapeutics Inc

Novartis AG

Onconova Therapeutics Inc

OncoTherapy Science Inc

Opsona Therapeutics Ltd

Oxstem Ltd

Pfizer Inc

Pharma Mar SA

Plexxikon Inc

Protagonist Therapeutics Inc

Rafael Pharmaceuticals Inc

Sanofi

Silence Therapeutics Plc

Stemline Therapeutics Inc

Sumitomo Dainippon Pharma Co Ltd

Sunesis Pharmaceuticals Inc

Takara Bio Inc

Teva Pharmaceutical Industries Ltd

Tolero Pharmaceuticals Inc

Trethera Corp

Trillium Therapeutics Inc

VasGene Therapeutics Inc

Myelodysplastic Syndrome Therapeutic Products under Development, Key Players in Myelodysplastic Syndrome Therapeutics, Myelodysplastic Syndrome Pipeline Overview, Myelodysplastic Syndrome Pipeline, Myelodysplastic Syndrome Pipeline Assessment


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand